Government grant to apply NanoCelle® to an RNA nasal vaccine
Medlab (ASX:MDC) receives Government grant to apply NanoCelle® to an RNA nasal vaccine in collaboration with University of NSW (UNSW) and Macquarie University (MQ) to fight COVID-19 future potential epidemics.
Friday 14th January 2022
Read more
Now this is scalable – a drug delivery platform rather than a drug itself
Listen to ASX-listed Medlab Clinical CEO Dr Sean Hall talk to Matt Birney on the Bulls N’ Bears Report on Deb Knight show on 873 am. (2GB), about Medlab’s development of a potent drug delivery platform that can potentially piggyback any drug to where it needs to go.
Friday 12th November 2021
Read more
Medlab Clinical Ltd (ASX:MDC) sells its Australian nutraceutical business to PharmaCare
We are pleased to announce the sale of the Australian-only part of its nutraceutical business to PharmaCare
Wednesday 27th October 2021
Read more
Annual Message to Shareholders October 2021
Once Medlab Clinical’s listing on the ASX six years ago its experienced team of scientists have made extraordinary advances in the creation and manufacture of unique, world-leading products and valuable intellectual property.
Wednesday 13th October 2021
Read moreEdison Group – Executive interview with CEO, Dr Sean Hall
In this video, Dr Sean Hall, Medlab’s co-founder and CEO, introduces us to Medlab and its lead programmes and discusses what we can expect from this fast-growing company over the coming months.
Sunday 29th August 2021
Read moreJefferies Healthcare Conference - 2021
Medlab outlines its growth strategy for US and global investors at the prestigious annual Jefferies Healthcare Conference.
Saturday 26th June 2021
Read moreMedlab Clinical talks upcoming Phase III NanaBis trial and NanoCelle partnering opportunities
Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall tells Proactive's Andrew Scott they're focused on achieving regulatory approval for its lead drug candidate NanaBis™.
Thursday 24th June 2021
Read moreSmall Caps interview of CEO Sean Hall
Small Caps interview of CEO Sean Hall
Thursday 22nd April 2021
Read more
Medlab mixes reality with Microsoft
Read the three featured stories from Microsoft about Medlab's adoption of mixed reality solutions including HoloLens 2 head-mounted devices with Dynamics 365
Wednesday 14th April 2021
Read more
NanaBis demonstrates continued improvement in pain scores
The first cohort of Observational Study patients completing 12-month treatment with NanaBis™ demonstrated continued improvement in pain scores.
Monday 12th April 2021
Read more
Medlab to be granted European patent for NanoCelle® drug delivery platform
European Patent Office issues Notice of Intention to grant Medlab Clinical patent for NanoCelle® drug delivery platform
Wednesday 7th April 2021
Read more
Novartis’ Managing Director of Oncology (ANZ/NZ) joins Medlab Clinical board
Medlab Clinical appoints Novartis' Managing Director of Oncology for Australia and New Zealand as Non-Executive Director.
Tuesday 23rd March 2021
Read more
11-13 LORD ST, BOTANY
BUILDING A, UNIT A5 – A6, BOTANY QUARTER
NSW, 2019, AUSTRALIA
OFFICE HOURS: 8:30AM - 5PM EST
AUS: 1300 369 570
AUS: +61 2 8188 0311
USA: +1 947 771 8119
UK: +44 20 8138 0311
FAX: +61 2 9699 3347
Email: [email protected]